SAN

77.92

+1.26%↑

UCB

248.2

+0.16%↑

SHL.DE

36.72

+0.11%↑

ARGX

582.6

-0.88%↓

VIE

31.7

+0.44%↑

SAN

77.92

+1.26%↑

UCB

248.2

+0.16%↑

SHL.DE

36.72

+0.11%↑

ARGX

582.6

-0.88%↓

VIE

31.7

+0.44%↑

SAN

77.92

+1.26%↑

UCB

248.2

+0.16%↑

SHL.DE

36.72

+0.11%↑

ARGX

582.6

-0.88%↓

VIE

31.7

+0.44%↑

SAN

77.92

+1.26%↑

UCB

248.2

+0.16%↑

SHL.DE

36.72

+0.11%↑

ARGX

582.6

-0.88%↓

VIE

31.7

+0.44%↑

SAN

77.92

+1.26%↑

UCB

248.2

+0.16%↑

SHL.DE

36.72

+0.11%↑

ARGX

582.6

-0.88%↓

VIE

31.7

+0.44%↑

Search

Syensqo SA

Fechado

47.06 2.84

Visão Geral

Variação de preço das ações

24h

Atual

Mín

45.28

Máximo

47.54

Indicadores-chave

By Trading Economics

Rendimento

-204M

-164M

Vendas

-229M

1.3B

EPS

1.07

Rendimento de Dividendos

3.6

Margem de lucro

-12.34

Funcionários

13,000

EBITDA

44M

343M

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.60%

2.47%

Próximos Ganhos

15 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-3.5B

4.5B

Abertura anterior

44.22

Fecho anterior

47.06

Syensqo SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de mar. de 2026, 23:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 de mar. de 2026, 22:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 de mar. de 2026, 21:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 de mar. de 2026, 23:59 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

23 de mar. de 2026, 23:59 UTC

Conversa de Mercado

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 de mar. de 2026, 23:50 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 de mar. de 2026, 23:37 UTC

Conversa de Mercado

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 de mar. de 2026, 22:42 UTC

Conversa de Mercado
Notícias Principais

Global Equities Roundup: Market Talk

23 de mar. de 2026, 22:42 UTC

Conversa de Mercado
Notícias Principais

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 de mar. de 2026, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 de mar. de 2026, 22:23 UTC

Conversa de Mercado

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 de mar. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 de mar. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 de mar. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 de mar. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 de mar. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 de mar. de 2026, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 de mar. de 2026, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 de mar. de 2026, 22:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 de mar. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 de mar. de 2026, 22:08 UTC

Conversa de Mercado

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 de mar. de 2026, 21:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 de mar. de 2026, 21:42 UTC

Conversa de Mercado

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 de mar. de 2026, 21:32 UTC

Ganhos

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 de mar. de 2026, 21:32 UTC

Ganhos

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 de mar. de 2026, 21:32 UTC

Ganhos

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 de mar. de 2026, 21:10 UTC

Notícias Principais

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

23 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

23 de mar. de 2026, 20:50 UTC

Conversa de Mercado
Ganhos
Notícias Principais

Basic Materials Roundup: Market Talk

Comparação entre Pares

Variação de preço

Syensqo SA Previsão

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Syensqo SA

Syensqo SA/NV operates as a science company worldwide. It operates through Materials, and Consumer & Resources segments. The company offers amine ether, amines, fatty amines, and specialty amines; antioxidants and stabilizers; composites; flavors and fragrances, such as vanillin, ethylvanillin, natural vanillin, and cyclopentanone; lithium salts, lithium cryolite, and lithium chemicals; diphenols and hydrocarbon monomers; and phosphorus specialties. It also provides biobased polymers, inverse emlusion polymers, monomers, specialty monomers, and synthetic polymers; solvents, including green solvents, flame retardants, and hydrocarbon; specialty chemicals; specicalty polymers comprising aromatic polyamides, aromatics, sulfones, fluorinated fluids, fluoropolymers, high performance polyester, polyethylene, polyolefin, and polyvinylidene chloride; and amphoteric, anionic, blend, cationic, and non-ionic surfactants. The company's products are used for transportation, aerospace, agro and feed, automotive, building, chemical, consumer goods, electronics, environment and energy, food, healthcare, home personal care, industrial, mining, and oil and gas markets. Syensqo SA/NV was founded in 1863 and is headquartered in Brussels, Belgium.
help-icon Live chat